Page last updated: 2024-10-24

negative regulation of isotype switching

Definition

Target type: biologicalprocess

Any process that stops, prevents, or reduces the frequency, rate or extent of isotype switching. [GOC:go_curators]

Negative regulation of isotype switching is a crucial process in the immune system, ensuring precise control of antibody production. This process involves the suppression of switching from one antibody isotype to another, preventing the generation of inappropriate antibodies. It is tightly regulated by a complex interplay of factors including:

1. **Transcriptional regulation:** Specific transcription factors and signaling pathways are involved in silencing the expression of germline transcripts, which initiate isotype switching.
2. **Chromatin modifications:** The chromatin structure surrounding the immunoglobulin heavy chain locus is modified to inhibit access of the switching machinery. This involves histone modifications like methylation and acetylation.
3. **Cytokine signaling:** Cytokines like IL-4 and IL-10 can negatively regulate isotype switching by inhibiting the production of key transcription factors required for the process.
4. **MicroRNA regulation:** Specific microRNAs can target and suppress the expression of transcripts involved in isotype switching.
5. **Competition for switching machinery:** Factors that promote isotype switching to one isotype can compete with factors that promote switching to another isotype, contributing to regulation.

The overall effect of these mechanisms is to limit inappropriate isotype switching, ensuring the production of antibodies that effectively neutralize pathogens while avoiding harmful autoimmunity. This regulation is critical for maintaining immune homeostasis and preventing uncontrolled antibody production.'
"

Proteins (1)

ProteinDefinitionTaxonomy
Protein mono-ADP-ribosyltransferase PARP3A protein mono-ADP-ribosyltransferase PARP3 that is encoded in the genome of human. [PRO:DNx, UniProtKB:Q9Y6F1]Homo sapiens (human)

Compounds (12)

CompoundDefinitionClassesRoles
pj-34PJ34 : A member of the class of phenanthridines that is 5,6-dihydrophenanthridine substituted at positions 2 and 6 by (N,N-dimethylglycyl)amino and oxo groups, respectively. It is a potent inhibitor of poly(ADP-ribose) polymerases PARP1 and PARP2 (IC50 of 110 nM and 86 nM, respectively) and exhibits anti-cancer, cardioprotective and neuroprotective properties.phenanthridines;
secondary carboxamide;
tertiary amino compound
angiogenesis inhibitor;
anti-inflammatory agent;
antiatherosclerotic agent;
antineoplastic agent;
apoptosis inducer;
cardioprotective agent;
EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor;
neuroprotective agent
3-aminobenzoic acid3-aminobenzoic acid : An aminobenzoic acid carrying an amino group at position 3.

3-aminobenzoic acid: RN given refers to parent cpd
aminobenzoic acid
4-Methoxybenzamidebenzamides
rucaparibAG14447: Poly(ADP-ribose) polymerase inhibitor; structure in first sourceazepinoindole;
caprolactams;
organofluorine compound;
secondary amino compound
antineoplastic agent;
EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor
latonduine alatonduine A: structure in first source
veliparibbenzimidazolesEC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor
olaparibcyclopropanes;
monofluorobenzenes;
N-acylpiperazine;
phthalazines
antineoplastic agent;
apoptosis inducer;
EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor
niraparib2-[4-(piperidin-3-yl)phenyl]-2H-indazole-7-carboxamide : A member of the class of indazoles that is 2H-indazole substituted by 4-(piperidin-3-yl)phenyl and aminocarbonyl groups at positions 2 and 7, respectively. It is a potent PARP1 inhibitor with IC50 of 3.2 nM.benzenes;
indazoles;
piperidines;
primary carboxamide
antineoplastic agent;
EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor
niraparibniraparib : A 2-[4-(piperidin-3-yl)phenyl]-2H-indazole-7-carboxamide that has S-configuration. It is a potent inhibitor of PARP1 and PARP2 (IC50 of 3.8 and 2.1 nM, respectively) and approved as a first-line maintenance treatment for women with advanced ovarian cancer after responding to platinum-based chemotherapy.

niraparib: structure in first source
2-[4-(piperidin-3-yl)phenyl]-2H-indazole-7-carboxamideantineoplastic agent;
apoptosis inducer;
EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor;
radiosensitizing agent
xav939XAV939 : A thiopyranopyrimidine in which a 7,8-dihydro-5H-thiopyrano[4,3-d]pyrimidine skeleton is substituted at C-4 by a hydroxy group and at C-2 by a para-(trifluoromethyl)phenyl group.

XAV939: selectively inhibits beta-catenin-mediated transcription; structure in first source
(trifluoromethyl)benzenes;
thiopyranopyrimidine
tankyrase inhibitor
bmn 673talazoparib: inhibits both PARP1 and PARP2; structure in first source
me0328ME0328: inhibits ARTD3; structure in first source